)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Krystal Biotech (KRYS) investor relations material
Krystal Biotech Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary3 Nov, 2025
Executive summary
Achieved $97.8 million in Vyjuvek net product revenue for Q3 2025, with launches expanding in Germany, France, and Japan, and strong U.S. performance supported by an updated label and growing reimbursement approvals.
Net income for Q3 2025 was $79.4 million, up significantly year-over-year, driven by higher sales, improved gross margin, and a one-time non-cash tax benefit.
The company is advancing a broad clinical pipeline, including programs in cystic fibrosis, alpha-1 antitrypsin deficiency, ophthalmology, oncology, dermatology, and aesthetics, with near-term readouts expected.
FDA granted platform technology designation for the HSV-1 gene delivery platform, currently for KB801, and approved an updated Vyjuvek label expanding eligible patient population and dosing flexibility.
Maintains a strong cash position with $864.2 million in cash and investments at quarter end.
Financial highlights
Q3 2025 product revenue was $97.8 million, up from $83.8 million in Q3 2024; nine-month revenue reached $282.0 million, up from $199.4 million year-over-year.
Gross margin for Q3 2025 was 96%, up from 92% in Q3 2024, due to U.S. manufacturing process optimizations.
Net income for Q3 2025 was $79.4 million (EPS basic $2.74, diluted $2.66), up from $27.2 million in Q3 2024; nine months net income was $153.4 million (EPS basic $5.31, diluted $5.14).
R&D expenses for Q3 2025 were $14.6 million; SG&A expenses were $37.6 million; non-cash stock-based compensation was $13.2 million.
Cash and investments totaled $864.2 million as of September 30, 2025.
Outlook and guidance
Expect continued steady growth in Vyjuvek patient inclusion in Europe and modest contribution from Japan in 2025, with greater impact in 2026.
Full-year non-GAAP R&D and SG&A guidance revised to $145–$155 million, excluding stock-based compensation.
No revenue guidance for 2026 due to multiple ongoing launches and distribution complexity.
Interim results for cystic fibrosis program (KB407) expected in Q4 2025, with additional pipeline updates in 2026.
Cash position sufficient to fund operations for at least 12 months from the filing date.
VYJUVEK: Impact of label/sales force on DEB reach
What specific efficiencies does platform designation bring?
How will growing ex-U.S. sales impact overall gross margin?
Vyjuvek global distributor network impact?
KB407 CF: What defines molecular success?
Platform designation impact on pipeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Krystal Biotech earnings date
Q4 202513 Feb, 2026
Next Krystal Biotech earnings date
Q4 202513 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Krystal Biotech Inc., known as Krystal Biotech, is a biotechnology firm engaged in the development and commercialization of genetic medicines targeting rare and serious diseases. The company focuses on creating treatments using gene therapy approaches, with a significant emphasis on dermatological conditions. Its product pipeline includes innovative therapies such as bercolagene telserpavec (B-VEC) for dystrophic epidermolysis bullosa, a severe skin disorder, and other treatments targeting conditions like autosomal recessive congenital ichthyosis and aesthetic skin conditions. Utilizing its proprietary skin TARgeted Delivery (STAR-D) platform, Krystal Biotech aims to advance treatments for various skin diseases, leveraging gene therapy's potential to offer long-term solutions. The company is headquartered in Pittsburgh, Pennsylvania, and its shares are listed on the NASDAQ under the ticker symbol KRYS.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage